Irvine, CA January 25, 2013 (PRWEB) January 25, 2013
EP Global Communications, Inc. (the Company), (Pink Sheets: EPGL.PK) is pleased to announce it has achieved a worldwide distribution Agreement for its upcoming medical devices now under development. "The EPGL Team felt it very important to establish a global network of distribution for our innovative devices, as a first priority". said David T. Markus, Ph.D. Vice President of BioMems technology development at the Company. "By establishing global reach early on, we can have the widest possible success for our devices and get them into the hands of medical professionals where they are needed as expeditiously as possible." The Company's Asian market partner, International Innovations of Singapore, lead by Andereas Markus as President, now has exclusive rights to Asia territories for distribution of EPGL medical device products and management of the international distribution network which is called EPGL International Innovations. "This network ties Asia, United States, Europe and Middle East distribution under one EPGL umbrella." said Michael Hayes, President of the Company. "We intend for EPGL medical devices to reach health care markets far and wide as they come on line. This deal achieves that objective out of the gate and that is significant for future revenues and growth of the Company". said Hayes.
MPDD RELEASE ANNOUNCEMENT AND MANUFACTURING
The Company will announce on March 29, 2013, the official release date of MPDD to happen within the second quarter, 2013. EPGL currently has over 8,000 physician names in our database worldwide. R&D for EPGL devices is done in Irvine, California at various facilities used by David T. Markus Ph.D., while manufacturing of EPGL medical devices is in San Diego, California at a proprietary manufacturing facility.
NEW MEDICAL DEVICES
The Company currently has six new medical devices under development which will use advanced, EPGL proprietary BioMems technology to improve performance in select areas of diagnosis and treatment. In addition to the planned MPDD release in second quarter 2013, the Company is developing the following devices: 1.) A device for more accurate treatment of muscle originated pain, called the MPTT. 2.) A device for significantly improved radio frequency ablation techniques is under development. 3.) A needle device for improved epidural accuracy is under development. 4.) A device for accurate, direct delivery of drugs to tissue and organs is under development. 5.) A device for more accurate delivery of stem cells therapy throughout the body is under development. 6.) A device for delivery of micro medical devices throughout the body is under development.
NEW TEAM MEMBERS
The Company welcomes Noah T. Kaufman, M.D. as Vice President of Emergency Medicine Innovations and candidate for Board of Directors. Dr. Kaufman will add valuable energy and insight from the perspective of emergency medicine, which is a significant market for EPGL moving into the future. He is a highly accomplished physician in his field. As Director of Clinical Emergency Ultrasound, Dr. Kaufman is in the top ranks for patient scores and outcomes. Dr. Kaufman is also currently the attending Emergency Physician for Barton Memorial Hospital ER and the Carson Valley Medical Center ER at South Lake Tahoe, California. His education includes Akron General Medical Center, Akron, OH - EM Residency 2006. Tulane University School of Medicine, New Orleans, LA - MD 2003, and University of Miami, Coral Gables, FL - BS 1996
The Company welcomes Mark Rea as Innovations Advisor and candidate for Board of Directors. After two successful startups, Mark co-founded Sionix Corp. In 1991. Sionix is currently in a joint venture to clean up the radioactive waste in the drinking water of Japan among other projects. Mark had the breakthrough concept that led to the current technology. After helping Sionix to go public he founded PlasTech Plus – a biodegradable plastic additive company. In the new bioplastic field the additive improves price and performance. In 2006 Mark founded PlastiCom – a manufacturer of bioplastic products. In the medical field Mark has developed a ‘cold laser’ for treatment of muscle and joint pain.
The Company welcomes Reid H. Erickson as Financial Partnership Strategy Advisor and candidate for Board of Directors. Reid is Founder, Chairman and CEO, Beneri International Corporation. He is an innovative, visionary leader spearheading green technology commercialization and the growth of sustainable businesses. With nearly three decades in the green and sustainable industry, Reid has assisted numerous early stage companies as an investor, advisor, consultant, board member or executive manager providing leadership and access to his worldwide network of entrepreneurial specialists dedicated to sustainable development.
The next major announcement updating shareholders on all progress will be made February 22, 2013. Please join selected EPGL Team members for a conference call today January 25, 2013 at 5PM EST. Up to 96 shareholders will be allowed to listen to the presentation and comments. Selected questions will be answered by the team. Call 605-475-4000. Enter Code 475116#
About EP Global Communications, Inc.
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.